By Fineline Cube 
Merck & Co., Inc. (MSD; NYSE: MRK) announced that clesrovimab injection, the world’s first single fixed‑dose, long‑acting respiratory syncytial virus (RSV) monoclonal antibody, has officially launched commercially in China. The product is indicated for the prevention of RSV‑caused lower respiratory tract infections (LRTI) in newborns and infants entering or born during their first RSV season, and is administered as a single fixed dose requiring no body‑weight measurement prior to injection. Clesrovimab was approved for marketing in China on 15 June 2026.
Commercial & Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Merck & Co., Inc. (MSD; NYSE: MRK) |
| Product | Clesrovimab injection |
| Class | Preventive, long‑acting monoclonal antibody (passive immunization) |
| Indication | Prevention of RSV‑caused lower respiratory tract infection in newborns and infants entering or born during their first RSV season |
| Dosing | Single fixed dose; no body‑weight measurement required |
| China Approval Date | 15 June 2026 (NMPA) |
| Commercial Launch | 9 September 2026 (China) |
| Pricing & Distribution | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Clesrovimab, a preventive, long‑acting monoclonal antibody — the world’s first RSV antibody deliverable as a single fixed dose.
- Target: The RSV fusion (F) glycoprotein, the viral surface protein mediating entry into host cells; binding neutralizes the virus before infection takes hold.
- Mechanism: Induces passive immunity by supplying ready‑made antibodies, providing direct, rapid, and durable protection against RSV — unlike vaccines, which require the immature infant immune system to mount its own response over weeks.
- Administration Advantage: The fixed‑dose regimen eliminates body‑weight measurement prior to injection, streamlining clinic and birth‑hospital workflow and reducing dosing‑error risk relative to weight‑banded antibody products.
- Duration: Engineered for long‑acting coverage intended to span an infant’s RSV season; specific duration data: Not disclosed in the announcement.
Market Impact & Outlook
- RSV Disease Burden: RSV is a leading viral cause of lower respiratory tract infection and infant hospitalization worldwide, with newborns in their first RSV season at highest risk of severe disease. China’s large annual birth cohort makes infant RSV prevention a significant public‑health priority. China‑specific epidemiological figures: Not disclosed.
- First‑in‑World Positioning: As the world’s first single fixed‑dose, long‑acting RSV monoclonal antibody, clesrovimab differentiates on operational simplicity — one dose, one needle, no weighing — a meaningful advantage for mass infant immunization in delivery rooms and community clinics.
- Speed to Market: The interval between China’s 15 June 2026 approval and the 9 September commercial launch — under three months — signals Merck’s operational readiness and the priority it places on China’s maternal‑child health market.
- Franchise Context: The launch positions Merck within the rapidly growing RSV prevention market, alongside maternal vaccines and weight‑based infant antibodies; commercial uptake, pricing, and inclusion in China’s immunization programs: Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial uptake, distribution, and market expectations for clesrovimab in China. Actual results may differ materially due to risks including pricing and reimbursement decisions, competitive dynamics in RSV prevention, manufacturing and supply constraints, and evolving public‑health recommendations.-Fineline Info & Tech